Therapeutic Response

IDH2 p.R172M status confers therapeutic sensitivity to Enasidenib in patients with Acute Myeloid Leukemia.

Statements

Source and description
Idhifa (enasidenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.